References

Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer

10.1056/nejmoa1704174 · 2017 · External reference

Enzalutamide with standard first-line therapy in metastatic prostate cancer

10.1056/nejmoa1903835 · 2019 · External reference

Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study

10.1200/jco.20.03488 · 2021 · External reference

Unresolved reference

External reference

Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: a retrospective cohort study

10.1016/j.urolonc.2023.03.013 · 2023 · External reference

First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis

10.1001/jamaoncol.2022.7762 · 2023 · External reference

Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer

10.4103/aja20242 · 2024 · External reference

Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor

10.1007/s10147-024-02637-6 · 2024 · External reference

Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

10.1038/s41598-021-89609-2 · 2021 · External reference

Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients

10.1007/s00345-022-04200-2 · 2022 · External reference

Screening for predictive factors of efficacy of second-generation androgen receptor axis-targeted agents in patients with high-risk metastatic hormone-sensitive prostate cancer

10.1002/pros.24855 · 2025 · External reference

Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for >/=24 weeks in Europe

10.1016/j.eururo.2017.07.035 · 2018 · External reference

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

10.1016/s1470-2045(19)30688-6 · 2019 · External reference

Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition

10.1158/1078-0432.ccr-21-1625 · 2021 · External reference

Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

10.1056/nejmoa1911206 · 2019 · External reference

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

10.1016/s1470-2045(14)70474-7 · 2014 · External reference

Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer

10.1056/nejmoa2107322 · 2021 · External reference

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial

10.1016/j.annonc.2025.05.011 · 2025 · External reference

Molecular characterization and clinical outcomes of primary Gleason pattern 5 prostate cancer after radical prostatectomy

2019 · External reference

Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: a meta-analysis

10.1002/cam4.3108 · 2020 · External reference

Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy

10.1002/pros.24802 · 2025 · External reference

Triplet versus doublet therapy in patients with metastatic hormone-sensitive prostate cancer

10.1038/s41598-026-44627-w · 2026 · External reference

Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial

10.2217/fon-2022-0433 · 2022 · External reference